Beta Bionics, Inc. (BBNX)
Nasdaq · Surgical & Medical Instruments & Apparatus · Manufacturing · CIK 1674632 · fiscal year ends in Dec
Closing price $17.58 on 29 Oct 2026; 52-week range $8.86 to $31.99.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $127.3M
- Revenue growth
- 43.7%
- Net income, last twelve months
- -$83.1M
- Earnings per share
- -$1.84
- Gross margin
- 58.6%
- Operating margin
- -72.7%
- Net margin
- -65.3%
- Free cash flow
- -$66.0M
- Return on equity
- -20.7%
- Market value
- $955.7M
- Cash
- $81.6M
- Debt
- $0
- Debt to equity
- 0.00
- Shares outstanding
- 54.4M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $100.3M | -$71.7M | -$73.2M | -$1.81 | -$56.2M | 10-K filed 24 Feb 2026 |
| FY2024 | 31 Dec 2024 | $65.1M | -$45.3M | -$54.8M | -$8.60 | -$51.7M | 10-K filed 25 Mar 2025 |
| FY2023 | 31 Dec 2023 | $12.0M | -$35.9M | -$44.1M | -$8.31 | -$32.8M | 10-K filed 25 Mar 2025 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q3 FY2026 | 30 Sep 2026 | $35.5M | -$24.4M | -$0.52 |
| Q2 FY2026 | 30 Jun 2026 | $32.0M | -$23.4M | -$0.53 |
| Q1 FY2026 | 31 Mar 2026 | $27.6M | -$21.9M | -$0.49 |
| Q4 FY2025 | 31 Dec 2025 | $32.1M | -$13.5M | -$0.30 |
| Q3 FY2025 | 30 Sep 2025 | $27.3M | -$14.2M | -$0.33 |
| Q2 FY2025 | 30 Jun 2025 | $23.2M | -$16.9M | -$0.39 |
| Q1 FY2025 | 31 Mar 2025 | $17.6M | -$28.7M | -$0.93 |
| Q4 FY2024 | 31 Dec 2024 | $20.4M | -$18.1M | -$2.70 |
Company events
The newest 8-K filings of 17 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 27 Oct 2026 | 8-K | Results | 2.02, 9.01 |
| 17 Sep 2026 | 8-K | Other events | 8.01, 9.01 |
| 15 Sep 2026 | 8-K | Investor update, Other events | 7.01, 8.01, 9.01 |
| 29 Jul 2026 | 8-K | Results | 2.02, 9.01 |
| 22 May 2026 | 8-K | Shareholder vote | 5.07 |
| 21 May 2026 | 8-K | Investor update, Other events | 7.01, 8.01, 9.01 |
| 21 Apr 2026 | 8-K | Results | 2.02, 9.01 |
| 17 Feb 2026 | 8-K | Results | 2.02, 9.01 |
| 30 Jan 2026 | 8-K | Other events | 8.01 |
| 8 Jan 2026 | 8-K | Results | 2.02, 9.01 |
| 28 Oct 2025 | 8-K | Results | 2.02, 9.01 |
| 29 Jul 2025 | 8-K | Results | 2.02, 9.01 |
Every filing
The newest filings with the SEC of 81 held.
| Filed | Form | Period |
|---|---|---|
| 27 Oct 2026 | 10-Q | 30 Sep 2026 |
| 27 Oct 2026 | 8-K | 27 Oct 2026 |
| 17 Sep 2026 | 8-K | 15 Sep 2026 |
| 15 Sep 2026 | 8-K | 14 Sep 2026 |
| 29 Jul 2026 | 10-Q | 30 Jun 2026 |
| 29 Jul 2026 | 8-K | 29 Jul 2026 |
| 22 May 2026 | 8-K | 21 May 2026 |
| 21 May 2026 | 8-K | 21 May 2026 |
| 21 Apr 2026 | 10-Q | 31 Mar 2026 |
| 21 Apr 2026 | 8-K | 21 Apr 2026 |
| 10 Apr 2026 | ARS | 31 Dec 2025 |
| 10 Apr 2026 | DEFA14A | – |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 27 Oct 2026 | Mensinger Mike, Chief Product Officer | Sale under a trading plan | 2,650 | $22.00 | $58.3K | 174,740 | 29 Oct 2026 |
| 26 Oct 2026 | Hopman Mark, Chief Commercial Officer | Sale under a trading plan | 821 | $20.00 | $16.4K | 54,513 | 28 Oct 2026 |
| 14 Oct 2026 | Hopman Mark, Chief Commercial Officer | Sale outside a trading plan | 775 | $17.35 | $13.4K | 55,334 | 16 Oct 2026 |
| 1 Oct 2026 | Hopman Mark, Chief Commercial Officer | Sale outside a trading plan | 370 | $18.96 | $7.0K | 56,109 | 5 Oct 2026 |
| 22 Sep 2026 | Jones Christy, Director | Sale under a trading plan | 6,430 | $23.00 | $147.9K | 19,564 | 23 Sep 2026 |
| 16 Sep 2026 | Hopman Mark, Chief Commercial Officer | Sale under a trading plan | 30,779 | $20.13 | $619.6K | 56,479 | 17 Sep 2026 |
| 16 Sep 2026 | Mensinger Mike, Chief Product Officer | Sale under a trading plan | 2,650 | $22.00 | $58.3K | 177,390 | 17 Sep 2026 |
| 14 Sep 2026 | Hopman Mark, Chief Commercial Officer | Sale under a trading plan | 775 | $15.52 | $12.0K | 86,382 | 15 Sep 2026 |
| 9 Sep 2026 | Hopman Mark, Chief Commercial Officer | Sale under a trading plan | 36,870 | $18.46 | $680.7K | 87,157 | 10 Sep 2026 |
| 3 Sep 2026 | Saint Sean, President & CEO | Sale under a trading plan | 5,641 | $20.08 | $113.3K | 398,429 | 4 Sep 2026 |
| 2 Sep 2026 | Hopman Mark, Chief Commercial Officer | Sale outside a trading plan | 5,327 | $19.11 | $101.8K | 124,027 | 3 Sep 2026 |
| 2 Sep 2026 | Russell Steven Jon, Chief Medical Officer | Sale outside a trading plan | 4,221 | $19.11 | $80.7K | 169,628 | 3 Sep 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 1 Oct 2026 | MARK HOPMAN, Officer | 2,660 | $50.5K | 1 Oct 2026 |
| 22 Sep 2026 | CHRISTINA JONES, Director | 8,942 | $197.1K | 22 Sep 2026 |
| 16 Sep 2026 | MICHAEL MENSINGER, Officer | 5,300 | $101.9K | 16 Sep 2026 |
| 16 Sep 2026 | MARK HOPMAN, Officer | 28,119 | $540.7K | 16 Sep 2026 |
| 9 Sep 2026 | MARK HOPMAN, Officer | 40,305 | $779.1K | 9 Sep 2026 |
| 3 Sep 2026 | Steven Jon Russell, Officer | 4,221 | $82.0K | 2 Sep 2026 |
| 3 Sep 2026 | Michael R. Mensinger, Officer | 4,375 | $84.9K | 2 Sep 2026 |
| 3 Sep 2026 | Mark Hopman, Officer | 5,327 | $103.4K | 2 Sep 2026 |
| 3 Sep 2026 | Sean Saint, Officer | 5,641 | $113.3K | 3 Sep 2026 |
| 3 Sep 2026 | Stephen Feider, Officer | 6,675 | $129.6K | 2 Sep 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 7 Oct 2026 | T. Rowe Price Associates, Inc. | 13G | 16.6% | 8.9M |
| 13 Aug 2026 | Farallon Capital Management, L.L.C. | 13G amended | 1.3% | 595.0K |
| 24 Jul 2026 | Divisadero Street Capital Management, LP | 13G | 6.9% | 3.1M |
| 15 May 2026 | Eventide Asset Management, LLC | 13G amended | 13.4% | 5.9M |
| 15 May 2026 | RTW Investments, LP | 13G amended | 4.5% | 2.0M |
| 12 May 2026 | Zone Healthcare Holdings, LLC | 13G amended | 8.1% | 3.6M |
| 8 May 2026 | Soleus Private Equity Fund II, L.P. | 13G amended | 9.8% | 4.4M |
| 26 Mar 2026 | The Vanguard Group | 13G amended | 0% | 0 |
| 23 Feb 2026 | Point72 Asset Management, L.P. | 13G | 5.2% | 2.3M |
| 17 Feb 2026 | RTW Investments, LP | 13G amended | 5.7% | 2.5M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 6.9M | +14.4% | 7.38 |
| 30 Sep 2026 | 6.0M | -43.05% | 3.25 |
| 15 Sep 2026 | 10.6M | +12.95% | 9.91 |
| 31 Aug 2026 | 9.4M | +25.43% | 9.01 |
| 14 Aug 2026 | 7.5M | -1.45% | 5.47 |
| 31 Jul 2026 | 7.6M | +15.06% | 6.02 |
| 15 Jul 2026 | 6.6M | -3.08% | 6.97 |
| 30 Jun 2026 | 6.8M | +45.9% | 5.9 |
Funds that hold it
From each fund's latest Form 13F.
155 funds held it at 30 Jun 2026: 80 added and 34 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| Eventide Asset Management, LLC | 6,253,673 | $98.1M | +308,185 |
| Soleus Capital Management, L.P. | 4,393,714 | $68.8M | +39,213 |
| Morgan Stanley | 4,266,822 | $66.9M | +39,188 |
| Sands Capital Alternatives, LLC | 3,708,043 | $58.1M | 0 |
| BlackRock, Inc. | 3,340,171 | $52.3M | +301,576 |
| Point72 Asset Management, L.P. | 2,254,683 | $35.3M | -270,357 |
| Vanguard Capital Management LLC | 1,782,346 | $27.9M | +54,369 |
| Vestal Point Capital, LP | 1,600,000 | $25.1M | -611,518 |
| RTW Investments, LP | 1,500,000 | $23.5M | -500,000 |
| Deerfield Management Company, L.P. | 1,324,000 | $20.7M | 0 |
Peers
Companies in the same industry.
- Stryker Corp. (SYK): revenue $25.8B, market value $119.5B
- 3M Co. (MMM): revenue $25.2B, market value $91.6B
- Boston Scientific Corp. (BSX): revenue $21.0B, market value $61.9B
- Becton Dickinson & Co. (BDX): revenue $20.8B, market value $54.0B
- Resmed Inc. (RMD): revenue $5.7B, market value $35.5B
- Dexcom Inc. (DXCM): revenue $5.1B, market value $29.8B
- West Pharmaceutical Services Inc. (WST): revenue $3.4B, market value $29.1B
- Medline Inc. (MDLN): revenue –, market value $27.5B
- Glaukos Corp. (GKOS): revenue $690.3M, market value $14.3B
- Solventum Corp. (SOLV): revenue $8.3B, market value $14.2B